A Phase 2 interventional study of trastuzumab in Urinary Tract Cancer, sponsored by Hoffmann-La Roche. Terminated at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-25.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Urologic Neoplasms with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Urologic Neoplasms · Germany.
Among the 13 studies in Urologic Neoplasms with a site in Germany, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2001, is one of 7 in phase 2, and was the 4th registered.
155 studies on the registry are indexed under Urologic Neoplasms; 40 are open to participants now.
Browse Urologic Neoplasms studies →2 of the 13 studies in Urologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Australia and 11 more countries
Ages 18+
Prof. Dr. med. Christian Gratzke · Sites in Germany
Ages 18+ · Men only
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 30 Urologic Neoplasms studies recruiting now, 24 (80%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 60 across 109 interventional studies indexed under Urologic Neoplasms.
Median enrollment 200 across the 10 interventional studies, 285 across the 2 observational. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 3 studies filed under Urologic Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Urologic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05614739Eli Lilly and CompanyFORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Urologic Neoplasms with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of intravenous Herceptin in patients with metastatic urothelial cancer with disease progression during platinum-based chemotherapy. The anticipated time on study treatment is until disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.
Drug: trastuzumab
Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
Also known as: Herceptin
Progression-Free Survival (PFS) - Percentage of Participants With an Event
PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause.
Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
Progression-Free Survival - Time to Event
The median time, in months, from the first study drug treatment to a PFS event.
Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
Percentage of Participants Progression Free at 12 and 24 Months
Time frame: Months 12 and 24
Overall Survival (OS) - Percentage of Participants With an Event
OS was defined as the time from the start of study treatment to date of death due to any cause.
Time frame: Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter
Overall Survival - Time to Event
The median time, in months, from the start of study treatment to an OS event.
Time frame: Screening, every 4 weeks during treatment (up to 37 weeks), at end of treatment, and every 3 months thereafter
Percentage of Participants Surviving at 12 and 24 Months
Time frame: Months 12 and 24
Percentage of Participants by Best Overall Response to Treatment
Per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal \[(short axis less than (\<)10 millimeters (mm)\]. No new lesions. Partial response (PR) was defined as greater than or equal to (≥)30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, or progressive disease (PD).
Time frame: Screening, every 3 months during treatment (up to 37 weeks), and at end of treatment
| Milestone | Trastuzumab Monotherapy |
|---|---|
| Started | 5 |
| Completed | 4 |
| Not completed | 1 |
| Withdrew: Trial was terminated by sponsor | 1 |
PFS was defined as the time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause.
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| Progression-Free Survival (PFS) - Percentage of Participants With an Event | 80.0 |
OS was defined as the time from the start of study treatment to date of death due to any cause.
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| Overall Survival (OS) - Percentage of Participants With an Event | 80.0 |
The median time, in months, from the start of study treatment to an OS event.
| months | Trastuzumab Monotherapy |
|---|---|
| Overall Survival - Time to Event | 14.7 (2.5 to NA) |
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| 12 Months | 60.0 (12.6 to 88.2) |
| 24 Months | 20.0 (0.8 to 58.2) |
The median time, in months, from the first study drug treatment to a PFS event.
| months | Trastuzumab Monotherapy |
|---|---|
| Progression-Free Survival - Time to Event | 2.5 (0.7 to NA) |
Per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Complete response (CR) was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal \[(short axis less than (\<)10 millimeters (mm)\]. No new lesions. Partial response (PR) was defined as greater than or equal to (≥)30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. Stable disease (SD) was defined as not qualifying for CR, PR, or progressive disease (PD).
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| SD | 20.0 |
| PD | 80.0 |
| SD/PD | 100.0 |
| percentage of participants | Trastuzumab Monotherapy |
|---|---|
| 12 Months | 20.0 (0.8 to 58.2) |
| 24 Months | 20.0 (0.8 to 58.2) |
Collected over Adverse events (AEs) and serious adverse events (SAEs) were recorded from study start to 30 days after the last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trastuzumab Monotherapy | — | 2/5 (40%) | 5/5 (100%) |
| Event | Trastuzumab Monotherapy |
|---|---|
| Pain - stomachGeneral disorders | 1/5 |
| Obstruction - GURenal and urinary disorders | 1/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/5 |
| Event | Trastuzumab Monotherapy |
|---|---|
| Pain - extremity, limbGeneral disorders | 1/5 |
| Pain - headacheGeneral disorders | 1/5 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/5 |
| HypertensionCardiac disorders | 1/5 |
| Constitutional symptoms - other (not specified)General disorders | 1/5 |
| DiarrhoeaGastrointestinal disorders | 1/5 |
| Infection - other (not specified)Infections and infestations | 1/5 |
| Infection with unknown absolute neutrophil count (ANC)Infections and infestations | 1/5 |
| Metabolic/laboratory - other (not specified)Metabolism and nutrition disorders | 1/5 |
Full analysis set (FAS) includes all participants who received study treatment.
| Age, Continuous(years) | Trastuzumab Monotherapy |
|---|---|
| Mean | 67.4 ± 8.2 |
| Sex: Female, Male(Participants) | Trastuzumab Monotherapy |
|---|---|
| Female | 0 |
| Male | 5 |
The record gives a start of Jan 2001, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2014, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab